Hyperglycemia modulates extracellular amyloid-β concentrations and neuronal activity in vivo.
暂无分享,去创建一个
D. Holtzman | M. Raichle | Thomas E Mahan | Courtney L. Sutphen | Emily E Caesar | S. Macauley | R. Perez | M. Stanley | S. Yamada | C. Sutphen
[1] Eric D. Vidoni,et al. Impaired glycemia increases disease progression in mild cognitive impairment , 2014, Neurobiology of Aging.
[2] Tzeng-Ji Chen,et al. Diabetes Mellitus and the Risk of Alzheimer’s Disease: A Nationwide Population-Based Study , 2014, PloS one.
[3] S. Haneuse,et al. Glucose levels and risk of dementia. , 2013, The New England journal of medicine.
[4] S. Craft,et al. Insulin and Alzheimer's disease: untangling the web. , 2012, Journal of Alzheimer's disease : JAD.
[5] Adam W. Bero,et al. Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of β-Amyloid in Mice with Alzheimer’s Disease Pathology , 2012, Science Translational Medicine.
[6] S. Craft. Alzheimer disease: Insulin resistance and AD—extending the translational path , 2012, Nature Reviews Neurology.
[7] S. M. de la Monte. Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer's Disease , 2012, Current Alzheimer research.
[8] Pierre J Magistretti,et al. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. , 2011, Cell metabolism.
[9] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[10] J. Morris,et al. Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.
[11] Jee Hoon Roh,et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition , 2011, Nature Neuroscience.
[12] Yan Wang,et al. Characterizing the Appearance and Growth of Amyloid Plaques in APP/PS1 Mice , 2009, The Journal of Neuroscience.
[13] T. Uehara,et al. Lactate production and neurotransmitters; evidence from microdialysis studies , 2008, Pharmacology Biochemistry and Behavior.
[14] Guojun Bu,et al. Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In Vivo , 2008, Neuron.
[15] Sheng-Nan Wu,et al. Glucose and hippocampal neuronal excitability: Role of ATP‐sensitive potassium channels , 2007, Journal of neuroscience research.
[16] Suzanne Craft,et al. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. , 2007, Current Alzheimer research.
[17] Colin G. Nichols,et al. KATP channels as molecular sensors of cellular metabolism , 2006, Nature.
[18] Steven Mennerick,et al. Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.
[19] Joanna L. Jankowsky,et al. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase , 2004 .
[20] D. Holtzman,et al. In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life , 2003, The Journal of Neuroscience.
[21] A Hofman,et al. Diabetes mellitus and the risk of dementia , 1999, Neurology.
[22] N. Rawson,et al. Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain , 1998, Brain Research.
[23] R. Shulman,et al. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[24] P. Magistretti,et al. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[25] R. DeFronzo,et al. Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.
[26] S. Monte. Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer's Disease , 2012 .
[27] M. Mattson,et al. The KATP channel activator diazoxide ameliorates amyloid-β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.
[28] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[29] D. Borchelt,et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. , 2004, Human molecular genetics.